Best Diversified Bank Stocks To Own For 2014

LONDON -- Another day, another record -- that's how it seems to be for the FTSE 100 lately. And today is no exception, as the index of top U.K. shares broke through the 6,800 barrier for the first time since the dot-com madness at the start of the century. We have seen strong company results lately, but is the optimism premature? Considering we're not out of the economic woods yet, things might be getting a bit too overheated just now.

But whatever the reasons for the mini-boom, let's take a look at three individual companies setting their own new records.

BP (LSE: BP  ) (NYSE: BP  )
Shares in BP ended yesterday on a 52-week record close of 477.7 pence and are slightly up on that at 482 pence at the time of writing. Over that period, the price has gained about 20% as the oil and gas giant emerges from the Gulf of Mexico disaster -- although the oil spill is still weighing on the company, as the full extent of the clean-up costs are as yet uncertain.

5 Best Shipping Stocks To Watch For 2015: Synergy Pharmaceuticals Inc (SGYP)

Synergy Pharmaceuticals, Inc., incorporated on February 11, 1992, is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�� lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�� active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors.

As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor. As of December 31, 2011, the Company was dosing patients in an 800-patient Phase II/III clinical trial of plecanatide to treat. It is also developing a second generation GC-C receptor analog, SP-333, which is in pre-clinical development for the treatment of gastrointestinal inflammatory diseases. SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone.

The Company competes with Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Takeda Pharmaceuticals America, Inc., Sucampo Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc. and Shire Plc.

Advisors' Opinion:

• [By Monica Gerson]

  Breaking news

  Time Warner Cable (NYSE: TWC) reported a drop in its third-quarter profit. Time Warner Cable's quarterly profit fell to $532 million, or $1.84 per share, from $808 million, or $2.60 per share, in the year-ago period. To read the full news, click here. Synergy Pharmaceuticals (NASDAQ: SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC). To read the full news, click here. Cigna (NYSE: CI) reported a 19% rise in its third-quarter earnings and lifted its full-year earnings outlook. To read the full news, click here. Charm Communications (NASDAQ: CHRM) announced today that the special committee of the Company's board of directors, consisting of independent directors Mr. Zhan Wang, Mr. Andrew J. Rickards and Mr. Gang Chen, has retained China Renaissance Securities (Hong Kong) Limited as its financial advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP as its legal advisor. To read the full news, click here.

  Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

• [By Sean Williams]

  Finally, Synergy Pharmaceuticals (NASDAQ: SGYP  ) may have had the wildest week of them all. Synergy's share price spiked 16% on Tuesday as an analyst at Cantor Fitzgerald raised her peak sales estimate for plecanatide, the company's midstage drug for chronic idiopathic constipation and irritable bowel syndrome with constipation, to $1.58 billion from $1.05 billion, as clinical data has been stronger than expected. However, the company didn't return the favor to shareholders by -- the very next day, mind you ��announcing a secondary offering of 16.375 million shares. The downside of clinical-stage companies is the always apparent risk of dilution. Shares have lost 25% since their Tuesday close.

Best Diversified Bank Stocks To Own For 2014: Beazer Homes USA Inc. (BZH)

Beazer Homes USA, Inc. designs, builds, and sells single-family and multi-family homes. The company offers homes for entry-level, move-up, or retirement-oriented buyers. It also engages in rental of previously owned homes that are purchased and improved by the company. The company sells its homes through commissioned new home sales counselors and independent brokers. It operates in 16 states, including Arizona, California, Delaware, Florida, Georgia, Indiana, Maryland, Nevada, New Jersey, New York, North Carolina, Pennsylvania, South Carolina, Tennessee, Texas, and Virginia. Beazer Homes USA, Inc. was founded in 1985 and is headquartered in Atlanta, Georgia.

Advisors' Opinion:

• [By Dan Caplinger]

  One sign of strength recently has come from Toll Brothers' resilience even in the face of higher interest rates. In its July quarter, Toll Brothers managed to see net new signed contracts rise at a 26% pace, more than doubling rival D.R. Horton's (NYSE: DHI  ) pace of growth. What's perhaps most impressive about those gains is that they defied big drops in order volumes at PulteGroup and Beazer Homes (NYSE: BZH  ) , both of which saw double-digit percentage decreases in orders during the same period.

• [By WWW.DAILYFINANCE.COM]
  Records fell on Wall Street Friday as another solid report on housing lifted the market for the second day in a row. There's a three-day weekend coming up -- something that often prompts investor caution -- but the gains were broad-based even though volume was fairly light. The VIX, which measures volatility, fell to its lowest level this year. The Dow Jones industrial average (^DJI) gained 63 points, the Nasdaq composite (^IXIC) rose 31, and the Standard & Poor's 500 index (^GPSC) added 8, topping the record high set last week. The Dow Transportation average also raced to an all-time high, lifted by airline stocks. United (UAL) soared more than 4 percent; Delta (DAL) gained more than 1 percent and Southwest (LUV) gained 2 percent. Southwest is at an all-time high, up 79 percent from a year ago. New home sales bounced back with a better than expected 6.4 percent increase last month. Lennar (LEN) and D.R. Horton (DHI) both rose 4 percent. Pulte (PHM), Beazer (BZH) and Hovnanian (HOV) also solid posted gains. Earnings continue to drive retail stocks. Gap (GPS) edged higher even though net fell. Foot Locker (FL) gained 1½ percent after topping expectations. GameStop (GME) rose 4 percent. Its net rose, helped by the rollout last year of new Xbox and PlayStation consoles. Zumiez (ZUMZ) rose 5½ percent on an earnings beat. But Aeropostale (ARO) tumbled 24 percent. Its loss widened and sales declined. The retailer continues to struggle with teen fashion trends. Also on the earnings front, TiVo (TIVO) rose 2 percent as it swung to a profit from a year ago loss. It also reported an increase in the number of subscribers. Hewlett-Packard (HPQ) rose 6 percent on news the company plans to eliminate up to 16,000 additional workers in an effort to cut costs. And several stocks extended big moves from yesterday. Best Buy (BBY) rose more than 3 percent for the second straight day after earnings beat expectations. Isis Pharmaceuticals (ISIS) jumped
• [By Sean Williams]

  While this is good news from the perspective that the Fed thinks the market is strong enough to move forward without any additional stimulus, it's terrible news for the housing sector, which has relied on low lending rates to drive loans. It's no surprise that last week was the worst one we've witnessed in the housing sector in more than a year -- especially for homebuilders still on the shakiest of ground, like Beazer Homes (NYSE: BZH  ) . Beazer, which is still losing money on an annualized basis, fell 10% on the week, despite seeing its revenue surge 50% in its most recent quarter.

• [By Erika Janowicz]

  Compass Point analyst Wilkes Graham updated his housing forecast:

  Graham increased assumed ROI's to 9% on average from 7%. Reduced targeted sector price/ book from $190% to 170%. Expects 20-30% growth in starts and new home sales in 2012 and 2013 to stabilize in 2014 and on at approximately 10%. For covered builders, the analyst lowered estimates by 8% and lowered price targets by 10%. Compass Point expects 10% annual growth in single family starts and new home sales and 2-5% pricing growth. Downgraded DR Horton Inc. (NYSE: DHI) from Buy to Neutral and KB Home (NYSE: KBH) from Neutral to Sell. DR Horton's and KB Home's PT was lowered from $23.50 to $20.00 and from $17.50 to $14.00, respectively. Graham reiterated a Buy rating on Ryland Group Inc. (NYSE: RYL) and Standard Pacific Corp. (NYSE: SPF). The analyst raised the PT on Ryland from $50.00 to $50.50 and lowered the PT on Standard Pacific from $10.00 to $9.50. Compass Point reiterated a Neutral rating on Beazer Homes USA Inc. (NYSE: BZH), Hovnanian Enterprises Inc. (NYSE: HOV), Lennar Corp. (NYSE: LEN), PulteGroup, Inc. (NYSE: PHM), and Toll Brothers Inc. (NYSE: TOL). The price target for Beazer and Hovnanian was raised from $15.50 to $24.00 and $5.00 to $5.75, respectively. Graham lowered the PT for Lennar, Pulte, and Toll to $34.50, $17.00, and $31.00.

  This Week's Data

Best Diversified Bank Stocks To Own For 2014: Tellabs Inc.(TLAB)

Tellabs, Inc. designs, develops, and supports telecommunications networking products for communication service providers in the United States and internationally. Its products and services enable customers to deliver wireless and wireline voice, data, and video services to business and residential customers. The company operates through three segments: Broadband, Transport, and Services. The Broadband segment provides access products that enable service providers to deliver bundled voice, video, and high-speed Internet/data services over copper or fiber networks; managed access products, which deliver wireless and business services primarily outside of North America; and data products, including packet-switched products that enable wireless and wireline carriers to deliver mobile voice and Internet services, and wireline business services to their customers. The Transport segment enables service providers to manage network bandwidth by adding capacity needed; and wireline and wireless providers to support metro networks, mobile services, and business services for enterprises, as well as triple-play voice, video, and data services for residential consumers. The Services segment delivers deployment, training, support, and professional services, which support various phases of the network, such as planning, building, and operating. Tellabs, Inc. serves primarily communication services providers, including local exchange carriers; wireline and wireless service providers; multiple system operators; competitive service providers; distributors; original equipment manufacturers; system integrators; and government agencies. The company sells its products and services through its direct sales and sales support personnel, value-added resellers, independent sales representatives, distributors, and public and private network providers. Tellabs, Inc. was founded in 1974 and is headquartered in Naperville, Illinois.

Advisors' Opinion:

• [By Rick Munarriz]

  Thursday
  Tellabs (NASDAQ: TLAB  ) checks in on Thursday. The provider of mobile backhaul, packet optical, and services solutions to communications services lost its CEO to colon cancer last year. It has also lost its mojo. Wall Street sees Tellabs merely breaking even in 2013 on a 14% decline in revenue.

Best Diversified Bank Stocks To Own For 2014: The Pantry Inc.(PTRY)

The Pantry, Inc. operates a chain of convenience stores in the southeastern United States. The company?s stores offer a selection of merchandise, fuel, and ancillary products and services. Its merchandise products include cigarettes, grocery and other tobacco products, packaged beverages, beer, and wine. The company operates stores under various selected banners, which primarily include Kangaroo Express. As of September 29, 2011, it operated 1,649 convenience stores located in Florida, North Carolina, South Carolina, Georgia, Alabama, Tennessee, Mississippi, Virginia, Kansas, Kentucky, Louisiana, Indiana, and Missouri; and 233 quick service restaurants. The company was founded in 1967 and is headquartered in Cary, North Carolina.

Advisors' Opinion:

• [By Sean Williams]

  Much of the same can be said about The Pantry (NASDAQ: PTRY  ) , a predominantly Southeastern U.S. convenience store chain that operates under the Kangaroo Express name. Food inflation has been minimal, the weather hasn't been as cooperative, and consumer traffic fell 4.6% in its most recent quarter. But where other investors see weakness, I see an opportunity.

• [By Jeremy Bowman]

  What: Shares of The Pantry (NASDAQ: PTRY  ) were down as much as 15% today after the convenience-store chain posted a second-quarter loss and missed Wall Street estimates.

Best Diversified Bank Stocks To Own For 2014: Medical Cannabis Payment Solutions (REFG.PK)

Medical Cannabis Payment Solutions, incorporated on December 1, 2005, is a provider of integrated supply and distribution technology. The Company�� Seed-to-Sale (S2S) integrated solution is a management and compliance technology for growers, caregivers and dispensaries in the market. The Company also works with public officials and government agencies to expand the acceptance of medicinal cannabis, and the adoption of a legal framework where maximum market expansion is possible. The Company solves the fragmentation problem by identifying tools that are important to dispensaries, and customizing those tools specifically catered to the industry. The Company's solutions include Spark, Ghost and S2S.

Spark

The Company�� SPARK Hosted Voice over Internet Protocol (VoIP) provides customers with enterprise-class hosted phone systems customized to fit customers��needs. SPARK's service is a fully-managed, cloud-based system. The Company offers the convenience of an online Internet Protocol (IP)-based telecommunications system while still delivering substantial savings to customers bottom line.

Ghost

By offering customers a customized, tailored mobile solution, the Company's Ghost Mobile Apps give a marketing tool with a texting and e-mail solution, keeping customers in constant contact with patients and clients. The Company creates an optimized experience in context to each device or screen size.

Advisors' Opinion:

• [By Alan Brochstein]

  Not too surprisingly, supply is starting to increase. We have seen some companies enter the space by expanding their own businesses, but there have been some reverse mergers lately too. I had mentioned Refill Energy (REFG.PK) recently (soon to be Medical Cannabis Financial Group), but earlier this month Promap (PMAP.OB) acquired 94% of Advanced Cannabis Solutions (link to 8-K). As an aside, I think that this company is worth considering given the management team and the business model. Investors should keep in the back of their mind that there are many companies that are quietly developing their business models and could become public over time, especially as the regulatory and legal landscapes improve.

Best Diversified Bank Stocks To Own For 2014: Brooks Automation Inc.(BRKS)

Brooks Automation, Inc. provides automation, vacuum, and instrumentation solutions for semiconductor manufacturing, life sciences, and clean energy markets worldwide. The company?s Brooks Product Solutions segment provides a range of products critical to technology equipment productivity and availability. This segment?s products include atmospheric and vacuum tool automation systems, atmospheric and vacuum robots and robotic modules, and cryogenic vacuum pumping, thermal management, and vacuum measurement solutions, which are used to create, measure, and control critical process vacuum applications. Its Brooks Life Science Systems segment offers automated sample management systems, including automated sample storage, automated blood fractionation equipment, sample preparation and handling equipment, consumables, parts, and support services to various life science customers, including pharmaceutical companies, biotechnology companies, biobanks, national laboratories, rese arch institutes, and research universities. The company?s Brooks Global Services segment provides a range of support services, including on and off-site repair services, on and off-site diagnostic support services, and installation services to enable the customers to maximize process tool uptime and productivity. This segment also offers spare part support services to end-user customers. Brooks Automation, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

Advisors' Opinion:

• [By Lauren Pollock]

  Brooks Automation Inc.'s(BRKS) fiscal fourth-quarter earnings fell 95% as the technology-products company’s revenue slipped on weak demand from semiconductor customers and a much smaller tax benefit. Results beat expectations, but the company gave a weak outlook for the first quarter. Shares edged lower.